Meurer Steffen K, Weiskirchen Ralf
Institute of Molecular Pathobiochemistry, Experimental Gene, and Clinical Chemistry, RWTH Aachen University, Aachen, Germany.
Front Pharmacol. 2018 Feb 12;9:98. doi: 10.3389/fphar.2018.00098. eCollection 2018.
We have identified a phenomenon occurring in the usage of proposed "specific" Mitogen-activated protein kinase (MAPK) inhibitors. We found that especially inhibitors of p38 potentiate the activation of other MAPKs in various cell types. This finding will have tremendous impact on the interpretation of all former studies using MAPK inhibitors.
我们已经确定了在使用拟议的“特异性”丝裂原活化蛋白激酶(MAPK)抑制剂过程中出现的一种现象。我们发现,尤其是p38抑制剂能增强多种细胞类型中其他MAPK的激活。这一发现将对所有以前使用MAPK抑制剂的研究的解读产生巨大影响。